Search anything
Welcome to Multibagg AI
Log in to access personalized features
Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Latest stock market news, company updates, and price movements. Stay updated with market trends, earnings insights, and investment analysis.
SEBI has extended IPO approval validity until September 30, 2026, and paused penalties for MPS non-compliance, offering relief to companies amid market volatility and geopolitical tensions.
Jubilant FoodWorks (JUBLFOOD) stock price fell over 10% on April 7, 2026, hitting a new 52-week low amid persistent bearish pressure and technical weakness.
Rising crude oil prices above $100 per barrel are creating significant headwinds for the Nifty 50, threatening corporate earnings, fueling inflation, and prompting brokerage downgrades.
Indian indices face a volatile session on April 8, with Nifty and Bank Nifty poised for a tug-of-war between buyers and sellers at critical levels.
India's healthcare sector is experiencing rapid expansion, driven by government policies, private investment, and rising demand, positioning key hospital and pharma stocks for significant growth.
Morgan Stanley has reduced India's real GDP growth forecast for FY27 to 6.2% from 6.5%, citing geopolitical tensions in West Asia and elevated crude oil prices.
Following an increased stake in Fortis Healthcare, IHH Healthcare plans to add 2,000 beds in India by 2028, targeting 25% operating margins and market leadership.
India's market regulator SEBI has extended the validity of IPO and rights issue approvals until September 30, 2026, amid geopolitical tensions and market volatility.
Aurobindo Pharma's subsidiary Eugia Pharma has received USFDA approval to market Dasatinib tablets, a generic cancer drug targeting a $1.8 billion US market.
Biocon has launched its denosumab biosimilars, Bosaya™ and Aukelso™, in the United States, targeting the $5 billion market for osteoporosis and cancer-related bone conditions.
Wipro is set to announce its Q4 FY26 results on April 16, 2026, with investors closely watching for Q1 FY27 guidance and management commentary.
The Dow Jones Industrial Average has entered a correction, falling 10% from its recent high, as the escalating US-Iran conflict drives oil prices higher and stokes global inflation concerns.
SEBI has announced a one-time relaxation, extending IPO approval validity and suspending penalties for MPS non-compliance for companies amid current market volatility.
India's market regulator SEBI has extended IPO approval validity and relaxed minimum public shareholding compliance deadlines until September 30, 2026, amid market volatility.
The RBI's Monetary Policy Committee is expected to hold the repo rate at 5.25% in its April 2026 meeting due to rising inflation risks from high oil prices.
HCL Technologies reports a strong fiscal year 2025 with a 10.8% rise in net profit to ₹17,399 crore and a 6.5% revenue increase to ₹1,17,055 crore.
